Renaissance Capital logo

ZBIO News

Immunology biotech Zenas BioPharma prices upsized IPO at $17 midpoint

Zenas BioPharma logo

Zenas BioPharma, a Phase 3 biotech developing therapies for autoimmune and inflammatory diseases, raised $225 million by offering 13.2 million shares at $17, within the range of $16 to $18. The company had previously planned to offer 11.8 million shares at the...read more

US IPO Week Ahead: A trio of biotechs kick off fall IPO market

CBLL

Updated Monday 9/9/24 Three biotechs are scheduled to complete IPOs this week.   Bicara Therapeutics (BCAX) plans to raise $200 million at an $865 million market cap. Its lead candidate, ficerafusp alfa, is a bifunctional...read more

Immunology biotech Zenas BioPharma sets terms for $200 million IPO

Zenas BioPharma logo

Zenas BioPharma, a Phase 3 biotech developing therapies for autoimmune and inflammatory diseases, announced terms for its IPO on Friday. The Waltham, MA-based company plans to raise $200 million by offering 11.8 million shares at a price range of $16 to $18. At...read more

Renaissance Capital's August IPO Market Update

Zenas BioPharma logo

Amid the typical summer slowdown, the month of August saw 7 small IPOs raise a combined $90 million, most of which were based in Asia. Activity rose slightly from last August, but was below the 10-year historical average by deal count (9 IPOs), and well below...read more